Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
DEA Revisits Proposed Ban On Two Psychedelic Compounds: Researchers Disagree, Insist On Hearings
The Drug Enforcement Administration (DEA) is revisiting its stance on the classification of two psychedelic compounds, 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC).
The agency has proposed both be listed as Schedule I substances under the Controlled Substances Act (CSA). If added to the Schedule I list, these compounds would be officially considered as having high abuse potential with no recognized medical use.
The evaluation is being disputed by experts. Three formal requests for a hearing were submitted, prompting a reconsideration by the agency. The listing raises concerns within the scientific community and companies developing neurological and medical research that rely on them. Learn more.
Russell Newcombe Dies – Legacy Of UK’s Longtime Harm Reduction Advocate, Committed Drug Researcher
April 4 was a sad day for the drug research and harm reduction advocate communities worldwide with the news of Russell Newcombe’s passing. A prominent figure in the field of harm reduction, the English psychologist and researcher played an active role in informing and advocating for harm reduction strategies on a global scale.
Researcher, lecturer, trainer and consultant on drug use and drug policy for some 40 years at various institutions and organizations across the globe, his main areas of interest included the psychosocial …